Renamed to RVL Pharmaceuticals plc in March 2022
OSMT - Osmotica Pharmaceuticals plc
NASDAQ
->
Healthcare
->
Biotechnology
Bridgewater,
United States
Type: Equity
OSMT price evolution
OSMT
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $8.35 | $99.78 | $109.21 | $114.05 |
| Short term investments | ||||
| Net receivables | $4.19 | $0.65 | $22.59 | $26.41 |
| Inventory | $0.82 | $1.02 | $16.95 | $17.93 |
| Total current assets | $23.39 | $249.48 | $161.35 | $173.15 |
| Long term investments | ||||
| Property, plant & equipment | $2.5 | $2.19 | $29.51 | $30.81 |
| Goodwill & intangible assets | $83.06 | $83.06 | $163.98 | $166.61 |
| Total noncurrent assets | $86.16 | $85.53 | $193.81 | $197.79 |
| Total investments | ||||
| Total assets | $109.55 | $335.01 | $355.17 | $370.95 |
| Current liabilities | ||||
| Accounts payable | $4.45 | $1.55 | $4.52 | $6.77 |
| Deferred revenue | ||||
| Short long term debt | $30.96 | $215.73 | $1.4 | $1.5 |
| Total current liabilities | $53.93 | $265.51 | $48.65 | $55.78 |
| Long term debt | $0.7 | $0.43 | $220.89 | $220.97 |
| Total noncurrent liabilities | $0.87 | $1.05 | $221.32 | $221.31 |
| Total debt | $31.66 | $216.16 | $222.29 | $222.46 |
| Total liabilities | $54.8 | $266.56 | $269.97 | $277.09 |
| Shareholders' equity | ||||
| Retained earnings | -$497.81 | -$479.95 | -$462.22 | -$452.61 |
| Other shareholder equity | -$2.23 | -$2.23 | -$2.23 | -$2.23 |
| Total shareholder equity | $54.75 | $68.45 | $85.2 | $93.86 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $114.05 | $95.86 | $70.83 | $34.74 |
| Short term investments | ||||
| Net receivables | $26.41 | $43.91 | $56.42 | $37.64 |
| Inventory | $17.93 | $21.3 | $24.38 | $16.95 |
| Total current assets | $173.15 | $172.63 | $172.39 | $115.14 |
| Long term investments | ||||
| Property, plant & equipment | $30.81 | $35.22 | $31.26 | $31.41 |
| Goodwill & intangible assets | $166.61 | $254.84 | $591.24 | $738.2 |
| Total noncurrent assets | $197.79 | $290.63 | $623.26 | $770.56 |
| Total investments | ||||
| Total assets | $370.95 | $463.25 | $795.64 | $885.7 |
| Current liabilities | ||||
| Accounts payable | $6.77 | $8.49 | $24.87 | $36.07 |
| Deferred revenue | ||||
| Short long term debt | $1.5 | $2.19 | $1.89 | $6.68 |
| Total current liabilities | $55.78 | $75.94 | $114.39 | $124.68 |
| Long term debt | $220.97 | $271.11 | $266.94 | $314.01 |
| Total noncurrent liabilities | $221.31 | $272.61 | $294.98 | $341.75 |
| Total debt | $222.46 | $273.3 | $268.83 | $320.69 |
| Total liabilities | $277.09 | $348.55 | $409.38 | $466.43 |
| Shareholders' equity | ||||
| Retained earnings | -$452.61 | -$373.02 | -$102.36 | |
| Other shareholder equity | -$2.23 | -$2.23 | -$1.85 | -$0.63 |
| Total shareholder equity | $93.86 | $114.71 | $386.27 | $419.27 |
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $2.2 | $11.51 | $23.88 | $34.53 |
| Cost of revenue | $1.15 | $0.71 | $13.49 | $17.18 |
| Gross Profit | $1.05 | $10.8 | $10.39 | $17.35 |
| Operating activities | ||||
| Research & development | $1.38 | $2.05 | $3.31 | $4.51 |
| Selling, general & administrative | $24.84 | $21.05 | $18.92 | $20.68 |
| Total operating expenses | $26.22 | $30.98 | $16.6 | $74.22 |
| Operating income | -$25.17 | -$20.18 | -$6.21 | -$56.87 |
| Income from continuing operations | ||||
| EBIT | -$16.8 | -$17.14 | -$6.12 | -$56.56 |
| Income tax expense | $0.32 | $0.09 | $0.53 | -$4.72 |
| Interest expense | $0.73 | $0.49 | $2.96 | $3.03 |
| Net income | ||||
| Net income | -$17.86 | -$17.73 | -$9.61 | -$54.87 |
| Income (for common shares) | -$17.86 | -$17.73 | -$9.61 | -$54.87 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $177.88 | $240.03 | $263.7 | $245.75 |
| Cost of revenue | $74.48 | $111.63 | $135.01 | $125.19 |
| Gross Profit | $103.4 | $128.4 | $128.69 | $120.56 |
| Operating activities | ||||
| Research & development | $19.7 | $32.32 | $48.76 | $42.69 |
| Selling, general & administrative | $81.96 | $93.03 | $74.24 | $56.95 |
| Total operating expenses | $173.84 | $409.1 | $227.23 | $172.63 |
| Operating income | -$70.44 | -$280.69 | -$98.54 | -$52.07 |
| Income from continuing operations | ||||
| EBIT | -$69.89 | -$279.81 | -$97.87 | -$56.59 |
| Income tax expense | -$4.7 | -$27.12 | -$9.27 | -$40.49 |
| Interest expense | $14.4 | $18.21 | $20.79 | $29.05 |
| Net income | ||||
| Net income | -$79.59 | -$270.9 | -$109.4 | -$45.15 |
| Income (for common shares) | -$79.59 | -$270.9 | -$109.4 | -$45.15 |
| (in millions $) | 30 Sep 2021 | 30 Jun 2021 | 31 Mar 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$17.86 | -$17.73 | -$9.61 | -$54.87 |
| Operating activities | ||||
| Depreciation | $7.49 | -$3.41 | $3.99 | $4.44 |
| Business acquisitions & disposals | $110.84 | $7.3 | ||
| Stock-based compensation | $4.85 | $0.57 | $1.18 | $1.09 |
| Total cash flows from operations | -$15.93 | -$2.92 | -$11.49 | -$8.25 |
| Investing activities | ||||
| Capital expenditures | -$0.24 | -$0.95 | -$0.42 | -$0.71 |
| Investments | ||||
| Total cash flows from investing | $110.6 | -$0.95 | $6.88 | -$0.71 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.13 | $0 | $0.14 | -$3.05 |
| Net borrowings | -$186.08 | -$5.3 | -$0.02 | -$0.03 |
| Total cash flows from financing | -$186.1 | -$5.56 | -$0.24 | -$3.08 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$91.42 | -$9.44 | -$4.84 | -$12.04 |
| (in millions $) | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 | 31 Dec 2017 |
|---|---|---|---|---|
| Net income | -$79.59 | -$270.9 | -$109.4 | -$45.15 |
| Operating activities | ||||
| Depreciation | $21.03 | $57.02 | $81.57 | $46.45 |
| Business acquisitions & disposals | -$12.5 | |||
| Stock-based compensation | $4.92 | $4.93 | $1.97 | |
| Total cash flows from operations | $17.59 | $33.57 | $37.56 | $57.84 |
| Investing activities | ||||
| Capital expenditures | -$3.08 | -$4.02 | -$4.13 | -$6.9 |
| Investments | ||||
| Total cash flows from investing | -$3.08 | -$4.02 | -$4.13 | -$19.4 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $54.56 | -$2.79 | $58.08 | |
| Net borrowings | -$50.13 | -$1.9 | -$54.48 | -$11.37 |
| Total cash flows from financing | $3.68 | -$4.69 | $3.6 | -$23.31 |
| Effect of exchange rate | $0.17 | -$0.94 | $0.06 | |
| Change in cash and equivalents | $18.19 | $24.86 | $37.03 | $15.13 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 83.28M |
| Revenue | $72.12M |
|---|---|
| EBITDA | -$84.12M |
| EBIT | -$96.62M |
| Net Income | -$100.07M |
| Revenue Q/Q | -96.16% |
| Revenue Y/Y | -64.52% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 0.68 |
| Cash/Share | 0.10 |
| EPS | -$1.20 |
|---|---|
| ROA | -34.19% |
| ROE | -132.43% |
| Debt/Equity | 2.95 |
|---|---|
| Net debt/EBITDA | -0.55 |
| Current ratio | 0.43 |
| Quick ratio | 0.42 |